Zhang Y - Search Results

1

Phase Ib/II study of safety and efficacy of low-dose decitabine-primed chemoimmunotherapy in patients with drug-resistant relapsed/refractory alimentary tract cancer.

Chen M, Nie J, Liu Y, Li X, Zhang Y, Brock MV, Feng K, Wu Z, Li X, Shi L, Li S, Guo M, Mei Q, Han W. Chen M, et al. Among authors: zhang y. Int J Cancer. 2018 Sep 15;143(6):1530-1540. doi: 10.1002/ijc.31531. Epub 2018 Apr 26. Int J Cancer. 2018. PMID: 29663379 Free PMC article. Clinical Trial.

2

Low-dose decitabine-based chemoimmunotherapy for patients with refractory advanced solid tumors: a phase I/II report.

Fan H, Lu X, Wang X, Liu Y, Guo B, Zhang Y, Zhang W, Nie J, Feng K, Chen M, Zhang Y, Wang Y, Shi F, Fu X, Zhu H, Han W. Fan H, et al. Among authors: zhang w, zhang y. J Immunol Res. 2014;2014:371087. doi: 10.1155/2014/371087. Epub 2014 May 21. J Immunol Res. 2014. PMID: 24963497 Free PMC article. Clinical Trial.

3

Low Dose Decitabine Combined with Taxol and Platinum Chemotherapy to Treat Refractory/Recurrent Ovarian Cancer: An Open-Label, Single-Arm, Phase I/II Study.

Fu X, Zhang Y, Wang X, Chen M, Wang Y, Nie J, Meng Y, Han W. Fu X, et al. Among authors: zhang y. Curr Protein Pept Sci. 2015;16(4):329-36. doi: 10.2174/138920371604150429155740. Curr Protein Pept Sci. 2015. PMID: 25929868 Clinical Trial.

4

Autologous T Cells Expressing CD30 Chimeric Antigen Receptors for Relapsed or Refractory Hodgkin Lymphoma: An Open-Label Phase I Trial.

Wang CM, Wu ZQ, Wang Y, Guo YL, Dai HR, Wang XH, Li X, Zhang YJ, Zhang WY, Chen MX, Zhang Y, Feng KC, Liu Y, Li SX, Yang QM, Han WD. Wang CM, et al. Among authors: zhang wy, zhang yj, zhang y. Clin Cancer Res. 2017 Mar 1;23(5):1156-1166. doi: 10.1158/1078-0432.CCR-16-1365. Epub 2016 Aug 31. Clin Cancer Res. 2017. PMID: 27582488 Clinical Trial.

5

Increased IFNγ⁺ T Cells Are Responsible for the Clinical Responses of Low-Dose DNA-Demethylating Agent Decitabine Antitumor Therapy.

Li X, Zhang Y, Chen M, Mei Q, Liu Y, Feng K, Jia H, Dong L, Shi L, Liu L, Nie J, Han W. Li X, et al. Among authors: zhang y. Clin Cancer Res. 2017 Oct 15;23(20):6031-6043. doi: 10.1158/1078-0432.CCR-17-1201. Epub 2017 Jul 13. Clin Cancer Res. 2017. PMID: 28706011 Clinical Trial.

6

The safety, efficacy, and treatment outcomes of a combination of low-dose decitabine treatment in patients with recurrent ovarian cancer.

Zhang Y, Mei Q, Liu Y, Li X, Brock MV, Chen M, Dong L, Shi L, Wang Y, Guo M, Nie J, Han W. Zhang Y, et al. Oncoimmunology. 2017 May 17;6(9):e1323619. doi: 10.1080/2162402X.2017.1323619. eCollection 2017. Oncoimmunology. 2017. PMID: 28932630 Free PMC article.

7

Addition of Low-Dose Decitabine to Anti-PD-1 Antibody Camrelizumab in Relapsed/Refractory Classical Hodgkin Lymphoma.

Nie J, Wang C, Liu Y, Yang Q, Mei Q, Dong L, Li X, Liu J, Ku W, Zhang Y, Chen M, An X, Shi L, Brock MV, Bai J, Han W. Nie J, et al. Among authors: zhang y. J Clin Oncol. 2019 Jun 10;37(17):1479-1489. doi: 10.1200/JCO.18.02151. Epub 2019 Apr 30. J Clin Oncol. 2019. PMID: 31039052 Clinical Trial.

8

Camrelizumab Plus Gemcitabine, Vinorelbine, and Pegylated Liposomal Doxorubicin in Relapsed/Refractory Primary Mediastinal B-Cell Lymphoma: A Single-Arm, Open-Label, Phase II Trial.

Mei Q, Zhang W, Liu Y, Yang Q, Rasko JEJ, Nie J, Liu J, Li X, Dong L, Chen M, Zhang Y, Shi L, Wu H, Han W. Mei Q, et al. Among authors: zhang w, zhang y. Clin Cancer Res. 2020 Sep 1;26(17):4521-4530. doi: 10.1158/1078-0432.CCR-20-0514. Epub 2020 Jun 4. Clin Cancer Res. 2020. PMID: 32499235 Clinical Trial.

9

Autologous CIK cell immunotherapy in patients with renal cell carcinoma after radical nephrectomy.

Zhang Y, Wang J, Wang Y, Lu XC, Fan H, Liu Y, Zhang Y, Feng KC, Zhang WY, Chen MX, Fu X, Han WD. Zhang Y, et al. Among authors: zhang wy. Clin Dev Immunol. 2013;2013:195691. doi: 10.1155/2013/195691. Epub 2013 Dec 9. Clin Dev Immunol. 2013. PMID: 24382970 Free PMC article. Clinical Trial.

10

Analysis of adverse events following the treatment of autologous cytokine-induced killer cells for adoptive immunotherapy in malignant tumour sufferers.

Zhang Y, Xia L, Zhang Y, Wang Y, Lu X, Shi F, Liu Y, Chen M, Feng K, Zhang W, Fu X, Han W. Zhang Y, et al. Among authors: zhang w. Expert Opin Biol Ther. 2015 Apr;15(4):481-93. doi: 10.1517/14712598.2015.988134. Epub 2014 Dec 1. Expert Opin Biol Ther. 2015. PMID: 25435128

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

258,528 results

Search Page

Filters